Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – August 2020

GlobalData's “Partnerships, Licensing, Investments, Mergers and Acquisitions Deals and Trends in Pharmaceuticals – August 2020” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in August 2020. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharma Intelligence Center deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, August 2020 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, August 2020 12

2.2.1 Siemens Healthineers to Acquire Varian for USD16.4 Billion 12

2.2.2 Johnson & Johnson Raises USD7.5 Billion in Public Offering of Notes 13

2.2.3 Johnson & Johnson to Acquire Momenta Pharma 13

2.2.4 Gilead Sciences and Tango Therapeutics Enter into Collaboration 14

2.2.5 Royalty Pharma Raises USD6 Billion in Private Placement of Notes 15

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, August 2020 16

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, August 2020 17

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 18

3.1 Pharmaceuticals & Healthcare, Global, M&A, August 2020 18

3.1.1 Top M&A Deals in August 2020 19

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, March 2020– August 2020 20

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, August 2020 21

3.2.1 Top Equity Offering Deals in August 2020 22

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, March 2020– August 2020 23

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, August 2020 25

3.3.1 Top PE/VC Deals in August 2020 26

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, August 2020 27

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, August 2020 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, March 2020–August 2020 30

3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, March 2020–August 2020 31

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, August 2020 32

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, March 2020– August 2020 34

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), August 2020 36

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, August 2020 37

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 38

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, March 2020– August 2020 40

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), March 2020– August 2020 41

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), March 2020– August 2020 42

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, August 2020 44

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, August 2020 44

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), August 2020 45

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), March 2020– August 2020 46

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), March 2020– August 2020 48

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), March 2020– August 2020 50

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), March 2020– August 2020 52

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, August 2020 53

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, August 2020 54

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, August 2020 54

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 55

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, August 2020 55

5.1.1 Oncology – Deals of the Month 56

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, August 2020 59

5.2.1 Central Nervous System – Deals of the Month 60

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, August 2020 63

5.3.1 Infectious Diseases – Deals of the Month 64

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, August 2020 66

5.4.1 Cardiovascular – Deals of the Month 67

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, August 2020 69

5.5.1 Immunology – Deal of the Month 70

5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, August 2020 72

5.6.1 Metabolic– Deals of the Month 73

5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Disorders, Deals, August 2020 75

5.7.1 Gastrointestinal – Deals of the Month 76

6 Deal Summary by Geography 78

6.1 Pharmaceuticals & Healthcare, North America Deals, August 2020 78

6.1.1 North America – Deals of the Month 79

6.2 Pharmaceuticals & Healthcare, Europe, Deals, August 2020 81

6.2.1 Europe – Deals of the Month 82

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, August 2020 83

6.3.1 Asia-Pacific – Deals of the Month 84

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, August 2020 86

6.4.1 Rest of the World – Deals of the Month 87

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 88

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, March 2020– August 2020 88

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, March 2020– August 2020 89

8 Further Information 90

8.1 Methodology 90

8.2 About GlobalData 91

8.3 Contact Us 91

8.4 Disclosure information 91

8.5 Disclaimer 92

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, August 2020 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), August 2020 17

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 19

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, August 2020 19

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, March 2020– August 2020 20

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 22

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, August 2020 22

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 24

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 26

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, August 2020 26

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, March 2020– August 2020 28

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), August 2020 29

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), March 2020– August 2020 30

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, March 2020– August 2020 31

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), March 2020– August 2020 33

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), March 2020– August 2020 35

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 36

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), August 2020 37

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 39

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, March 2020– August 2020 41

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), March 2020– August 2020 43

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 44

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 45

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), March 2020– August 2020 47

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), August 2020 49

Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, March 2020– August 2020 51

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), August 2020 53

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, August 2020 53

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, August 2020 54

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, August 2020 54

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 56

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 60

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 64

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 67

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 70

Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 73

Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 76

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 79

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 82

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 84

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 87

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), March 2020– August 2020 88

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), March 2020– August 2020 89

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), March 2020– August 2020 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), August 2020 16

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), August 2020 17

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), March 2020– August 2020 18

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, March 2020– August 2020 20

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), March 2020– August 2020 21

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), March 2020– August 2020 23

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), March 2020– August 2020 25

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, March 2020– August 2020 27

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), August 2020 28

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), August 2020 29

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), March 2020– August 2020 30

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), March 2020– August 2020 32

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), March 2020– August 2020 34

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 36

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 38

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, March 2020– August 2020 40

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, March 2020– August 2020 41

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), March 2020– August 2020 42

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), March 2020– August 2020 44

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 45

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), March 2020– August 2020 46

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), March 2020– August 2020 48

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, March 2020– August 2020 50

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), March 2020– August 2020 51

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), August 2020 52

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), March 2020– August 2020 55

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), March 2020– August 2020 59

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), March 2020– August 2020 63

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), March 2020– August 2020 66

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), March 2020– August 2020 69

Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 72

Figure 33: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), March 2020– August 2020 75

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), March 2020– August 2020 78

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), March 2020– August 2020 81

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), March 2020– August 2020 83

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), March 2020– August 2020 86

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), March 2020– August 2020 88

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), March 2020– August 2020 89

    Pricing

Discounts available for multiple purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports